Ionis Pharmaceuticals’ olezarsen reduces pancreatitis by 85% in late-stage sHTG trial

Ionis Pharmaceuticals Inc. (Nasdaq: IONS) has reported a major clinical breakthrough in the treatment of severe hypertriglyceridemia (sHTG) with the release of its pivotal Phase 3 CORE and CORE2 trial data for olezarsen. Presented as a late-breaking clinical update at the American Heart Association (AHA) Scientific Sessions in New Orleans and published simultaneously in The New England Journal of Medicine, the study showed that olezarsen achieved a statistically significant and clinically meaningful reduction in fasting triglyceride levels, with results sustained over a full 12-month treatment period.

According to the data, olezarsen reduced fasting triglycerides by up to 72 percent versus placebo at six months, with 86 percent of patients reaching levels below 500 mg/dL, the threshold above which the risk of acute pancreatitis significantly rises. Even more notably, the drug was associated with an 85 percent reduction in acute pancreatitis events over the trial period, marking the first time any investigational treatment has demonstrated such an impact in this patient population. The data provide a strong foundation for a forthcoming supplemental new drug application filing with the U.S. Food and Drug Administration, which Ionis Pharmaceuticals plans to complete by the end of 2025.

Olezarsen, which is already approved in the United States and European Union under the name TRYNGOLZA for patients with familial chylomicronemia syndrome (FCS), is now positioned as a potentially first-in-class treatment for a broader sHTG population, a market that includes more than three million individuals in the United States alone.

What makes the Phase 3 CORE and CORE2 trials a clinical turning point for triglyceride management?

The CORE and CORE2 studies represent the most comprehensive clinical program conducted to date in severe hypertriglyceridemia. The trials enrolled a combined total of 1,063 patients with fasting triglyceride levels of 500 mg/dL or higher, all of whom were on standard-of-care lipid-lowering regimens. Participants were randomized to receive either 50 mg or 80 mg of olezarsen or placebo via subcutaneous injection every four weeks for 12 months.

Both studies met their primary endpoint, demonstrating up to 72 percent placebo-adjusted reductions in triglyceride levels at six months, with reductions maintained through the full year. Subgroup analysis showed that 89 percent and 88 percent of patients receiving 50 mg and 80 mg doses of olezarsen, respectively, achieved triglyceride levels below 880 mg/dL. Furthermore, 34 percent and 54 percent of those in the 50 mg and 80 mg arms, respectively, reached normal triglyceride levels of under 150 mg/dL.

Beyond lipid reduction, olezarsen led to a statistically significant 85 percent reduction in acute pancreatitis events over the 12-month study period. In the placebo group, there were 22 events in 17 patients, compared to seven events in five patients on olezarsen. These results corresponded to a number needed to treat (NNT) of 20 to prevent one pancreatitis event in the general sHTG population and just four in high-risk patients, such as those with triglyceride levels of 880 mg/dL or higher and a history of pancreatitis.

How does olezarsen’s mechanism of action differentiate it from traditional sHTG therapies?

Olezarsen is an investigational RNA-targeted therapeutic designed to inhibit the production of apolipoprotein C-III (apoC-III), a key regulator of triglyceride metabolism produced by the liver. Elevated apoC-III levels are strongly associated with high triglycerides and an increased risk of pancreatitis and cardiovascular events. By reducing apoC-III expression, olezarsen lowers triglyceride levels through a novel biological pathway not targeted by fibrates, omega-3 fatty acids, or statins.

In the trials, olezarsen demonstrated additional lipid-modulating benefits, including significant reductions in non-HDL cholesterol, remnant cholesterol, and apoC-III levels, aligning with a favorable metabolic profile. These secondary endpoint results support the possibility that olezarsen may offer broader cardiometabolic advantages beyond its core indication.

How does the safety and tolerability profile of olezarsen support long-term use in broader populations?

Ionis Pharmaceuticals reported that olezarsen maintained a favorable safety and tolerability profile throughout the duration of the CORE and CORE2 trials. Overall adverse event rates were comparable across study arms, with 75 percent of patients in the placebo group, 75 percent in the 50 mg olezarsen group, and 76 percent in the 80 mg group experiencing at least one treatment-emergent adverse event. Serious adverse events were less frequent in the olezarsen arms, with incidences of 9 percent in the 50 mg cohort and 11 percent in the 80 mg cohort, compared to 14 percent in the placebo group.

The most common side effects were mild injection site reactions, observed in 10 percent of patients in the 50 mg group, 17 percent in the 80 mg group, and only 1 percent in the placebo group. Other safety signals were consistent with prior studies of apoC-III-targeting therapies. Liver enzyme elevations greater than three times the upper limit of normal occurred in 7 percent of patients in the 80 mg group and 2 percent in placebo, but these elevations were asymptomatic and resolved without discontinuation. There were no Hy’s law cases reported.

There were modest increases in liver fat content and hemoglobin A1c levels with olezarsen treatment, consistent with prior experience. These changes were not associated with clinical complications and appeared manageable over the course of therapy.

What does investor sentiment suggest about Ionis Pharmaceuticals’ commercial trajectory with olezarsen?

Ionis Pharmaceuticals’ share price responded modestly in the wake of the AHA announcement, reflecting a cautious optimism from institutional investors. Analysts have long viewed the expansion into severe hypertriglyceridemia as a critical commercial inflection point for Ionis Pharmaceuticals, which has historically focused on rare diseases. The broader sHTG indication represents a significantly larger market opportunity and marks the company’s entry into more competitive therapeutic territory.

Analysts believe that olezarsen’s ability to prevent acute pancreatitis, a high-cost, high-burden clinical outcome, will be a compelling narrative in payer negotiations. Preventing just one pancreatitis event can save thousands of dollars in emergency hospitalization and reduce long-term complications, offering a strong health economic argument for adoption. However, reimbursement strategies and pricing will remain key variables as Ionis Pharmaceuticals approaches a 2026 launch window.

The company has stated that olezarsen will be one of two major product launches in 2026, and it is already preparing for commercial rollout across both orphan and general population segments. The high continuation rate into the open-label extension trial, which has been reported at over 90 percent, suggests strong patient and physician buy-in, which could support early uptake.

How does olezarsen’s approval pathway compare to other RNA-based therapies in metabolic diseases?

Olezarsen represents a growing shift in RNA-targeted medicines moving beyond rare genetic conditions toward common metabolic diseases. While Ionis Pharmaceuticals has developed multiple RNA-based therapies for niche indications, the success of olezarsen in a large-scale, high-prevalence disorder is seen as a maturation of the company’s development model.

The firm is also pursuing similar strategies in cardiovascular disease and other lipid-related conditions, with several RNA therapies in earlier stages of development. The positive readout from CORE and CORE2 bolsters confidence in this platform and sets a precedent for future regulatory and commercial pathways in mainstream metabolic care.

An FDA submission for olezarsen in sHTG is expected by the end of 2025. Approval in the United States could be followed by regulatory filings in Europe and other major markets, building on the infrastructure already established through TRYNGOLZA’s approval for familial chylomicronemia syndrome.

How could olezarsen’s Phase 3 success reshape long‑term treatment practice, payer positioning, and regulatory strategy for severe hypertriglyceridemia patients?

The pivotal data for olezarsen mark a watershed moment in the treatment of severe hypertriglyceridemia. With statistically significant reductions in both triglyceride levels and acute pancreatitis risk, Ionis Pharmaceuticals is now positioned to bring the first-ever disease-modifying therapy to a population with limited existing options. If regulatory milestones proceed as planned, olezarsen could become a foundational therapy not just for rare lipid disorders but for millions of at-risk patients with unmet clinical needs.

Key takeaways from Ionis Pharmaceuticals’ olezarsen Phase 3 trial results in severe hypertriglyceridemia

• Olezarsen achieved a placebo-adjusted reduction in fasting triglycerides of up to 72 percent at six months, sustained over 12 months.
• 86 percent of patients on olezarsen reached triglyceride levels below 500 mg/dL, a key threshold for reducing the risk of acute pancreatitis.
• The drug showed an 85 percent reduction in adjudicated acute pancreatitis events, the first such result reported in sHTG clinical trials.
• Nearly 90 percent of patients in the high-risk group (TG ≥880 mg/dL with prior pancreatitis) saw meaningful clinical benefit.
• The number needed to treat (NNT) was just four in high-risk patients to prevent one acute pancreatitis event over one year.
• Safety and tolerability were favorable, with only mild injection site reactions reported and no major hepatic safety concerns.
• Over 90 percent of patients from the CORE and CORE2 studies transitioned into the ongoing open-label extension study.
• Ionis Pharmaceuticals is targeting a 2026 commercial launch, following a planned FDA filing by the end of 2025.
• Institutional sentiment remains cautiously optimistic, driven by the drug’s potential to expand RNA-based therapies into cardiometabolic diseases.